1,2,3,4-Tetrahydro-6-methoxy-3-(methoxycarbonyl)-2-oxo-4-quinoline acetic acid, methyl ester | 125810-74-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1,2,3,4-Tetrahydro-6-methoxy-3-(methoxycarbonyl)-2-oxo-4-quinoline acetic acid, methyl ester
• 英文别名: methyl 6-methoxy-4-(2-methoxy-2-oxoethyl)-2-oxo-3,4-dihydro-1H-quinoline-3-carboxylate
• CAS: 125810-74-4
• 化学式: C₁₅H₁₇NO₆
• 分子量: 307.303
• InChiKey: HNAKXHXPQGCLHH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  90.9
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1,2,3,4-Tetrahydro-6-methoxy-3-(methoxycarbonyl)-2-oxo-4-quinoline acetic acid, methyl ester 在 吗啉 、 sodium hydride 、 二异丁基氢化铝 、 sodium chloride 作用下， 以 水 、 二甲基亚砜 、 甲苯 为溶剂， 生成 1,2,3,4-tetrahydro-6-methoxy-1-methyl-2-oxo-4-quinolineacetaldehyde
  参考文献：
  名称：

  Synthesis and carbamoylation of 1,2,3,4,5,6-hexahydro-1,3-dimethyl-2,6-methano-1,3-benzodiazocin-8-ol: bridged analogues of physostigmine

  摘要：

  The synthesis and carbamoylation of 2,6-methano-1,3-benzodiazocin-8-ol is described. A one pot silyl-aryl ether to carbamate transformation was developed. The compounds are analogues of the cholinesterase inhibitor physostigmine.

  DOI：

  10.1016/0040-4039(92)88151-t
• 作为产物：
  描述：

  methyl (E)-3-(5-methoxy-2-nitrophenyl)acrylate 在 titanium(III) chloride 、 4-polyvinylpyridine 、 ammonium acetate 、 sodium methylate 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 生成 1,2,3,4-Tetrahydro-6-methoxy-3-(methoxycarbonyl)-2-oxo-4-quinoline acetic acid, methyl ester
  参考文献：
  名称：

  Synthesis and carbamoylation of 1,2,3,4,5,6-hexahydro-1,3-dimethyl-2,6-methano-1,3-benzodiazocin-8-ol: bridged analogues of physostigmine

  摘要：

  The synthesis and carbamoylation of 2,6-methano-1,3-benzodiazocin-8-ol is described. A one pot silyl-aryl ether to carbamate transformation was developed. The compounds are analogues of the cholinesterase inhibitor physostigmine.

  DOI：

  10.1016/0040-4039(92)88151-t

文献信息

• Process of preparing 2,6-methano-1,3-benzodiazocine compounds
  申请人：Hoechst-Roussel Pharmaceuticals Inc.

  公开号：US05264575A1

  公开（公告）日：1993-11-23

  Novel 2,6-methano-1,3-benzodiazocines, intermediates, processes for the preparation thereof, and methods for alleviating pain and for alleviating various memory dysfunctions characterized by a decreased cholinergic function, such as Alzheimer's disease, utilizing compounds or compositions thereof are disclosed.

  本发明公开了一种新型的2,6-甲氧基-1,3-苯并二氮杂环化合物，以及其中间体和制备方法，还公开了利用这些化合物或组合物缓解疼痛和缓解由于胆碱能功能降低而表现为不同记忆功能障碍（例如阿尔茨海默病）的方法。
• 2,6-methano-1,3-benzodiazocine compounds which have useful
  申请人：Hoechst-Roussel Pharmaceuticals, Inc.

  公开号：US05010083A1

  公开（公告）日：1991-04-23

  Novel 2,6-methano-1,3-benzodiazocines, intermediates, processes for the preparation thereof, and methods for alleviating pain and for alleviating various memory dysfunctions characterized by a decreased cholinergic function, such as Alzheimer's disease, utilizing compounds or compositions thereof are disclosed.

  本发明揭示了2,6-甲基-1,3-苯并二氮杂环类化合物、中间体、其制备方法以及利用这些化合物或组合物缓解疼痛和缓解各种记忆功能障碍的方法，这些障碍的特点是胆碱能功能降低，如阿尔茨海默病。
• 2,6-methano-1,3-benzodiazocine compounds
  申请人：Hoechst-Roussel Pharmaceuticals Inc.

  公开号：US05097033A1

  公开（公告）日：1992-03-17

  Novel 2,6-methano-1,3-benzodiazocines, intermediates, processes for the preparation thereof, and methods for alleviating pain and for alleviating various memory dysfunctions characterized by a decreased cholinergic function, such as Alzheimer's disease, utilizing compounds or compositions thereof are disclosed.

  本发明涉及一种新型的2,6-甲基-1,3-苯并二氮杂环化合物、中间体、其制备方法以及利用其化合物或组合物缓解疼痛和缓解由乙酰胆碱能功能降低引起的各种记忆功能障碍，例如阿尔茨海默病的方法。
• Synthesis and carbamoylation of 1,2,3,4,5,6-hexahydro-1,3-dimethyl-2,6-methano-1,3-benzodiazocin-8-ol: bridged analogues of physostigmine
  作者：David M. Fink、Richard C. Allen

  DOI：10.1016/0040-4039(92)88151-t

  日期：1992.4

  The synthesis and carbamoylation of 2,6-methano-1,3-benzodiazocin-8-ol is described. A one pot silyl-aryl ether to carbamate transformation was developed. The compounds are analogues of the cholinesterase inhibitor physostigmine.